These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 3318429)

  • 61. Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial.
    Kivitz AJ; Greenwald MW; Cohen SB; Polis AB; Najarian DK; Dixon ME; Moidel RA; Green JA; Baraf HS; Petruschke RA; Matsumoto AK; Geba GP;
    J Am Geriatr Soc; 2004 May; 52(5):666-74. PubMed ID: 15086644
    [TBL] [Abstract][Full Text] [Related]  

  • 62. NSAIDs for the new decade--nabumetone?
    Huskisson EC
    Eur J Rheumatol Inflamm; 1991; 11(3):1-2. PubMed ID: 1365475
    [No Abstract]   [Full Text] [Related]  

  • 63. [Evaluation of tolerability and efficacy of a nabumetone preparation in the treatment of patients with rheumatoid arthritis].
    Alianti M; Lotta C; Vaiani G
    Clin Ter; 1990 Jun; 133(5):299-308. PubMed ID: 2143713
    [TBL] [Abstract][Full Text] [Related]  

  • 64. An open label study to establish dosing recommendations for nabumetone in juvenile rheumatoid arthritis.
    Goodman S; Howard P; Haig A; Flavin S; Macdonald B
    J Rheumatol; 2003 Apr; 30(4):829-31. PubMed ID: 12672207
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Properties and features of nabumetone].
    Davies NM; McLachlan AJ
    Drugs; 2000; 59 Spec No 1():25-33. PubMed ID: 10841070
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Economic and gastrointestinal safety comparisons of etodolac, nabumetone, and oxaprozin from insurance claims data from patients with arthritis.
    Simon LS; Zhao SZ; Arguelles LM; Lefkowith JB; Dedhiya SD; Fort JG; Johnson KE
    Clin Ther; 1998; 20(6):1218-35; discussion 1192-3. PubMed ID: 9916614
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone.
    Weaver AL; Messner RP; Storms WW; Polis AB; Najarian DK; Petruschke RA; Geba GP; Tershakovec AM
    J Clin Rheumatol; 2006 Feb; 12(1):17-25. PubMed ID: 16484875
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Double-blind evaluation of piroxicam and naproxen following missed dosage in patients with inflammatory arthritis.
    Langley GB; Fowles M; Sirett P; Vlieg M; Wigley RD
    N Z Med J; 1985 Jun; 98(781):490-2. PubMed ID: 3892383
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Nabumetone compared with indomethacin in the treatment of osteoarthritis in general practice.
    Carle WK; Wade AG; Kill DC; Poland M
    J Rheumatol Suppl; 1992 Nov; 36():58-62. PubMed ID: 1474536
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Upper gastrointestinal safety with nabumetone.
    Roth SH
    J Rheumatol Suppl; 1992 Nov; 36():74-9. PubMed ID: 1474539
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A 12-month postmarketing surveillance study of nabumetone. A preliminary report.
    Jenner PN
    Drugs; 1990; 40 Suppl 5():80-6. PubMed ID: 2081502
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical evaluation of a new controlled-release formulation of naproxen in osteoarthritis and rheumatoid arthritis. Canadian Multicentre Study Group.
    Curr Med Res Opin; 1988; 11(1):16-27. PubMed ID: 2898319
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinical efficacy and tolerance of nabumetone in articular and non-articular rheumatic disorders: personal experience during 12 weeks of treatment.
    Coaccioli S; Allegra A; Di Cato L; Puxeddu A
    Panminerva Med; 1998 Jun; 40(2):110-5. PubMed ID: 9689831
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Nabumetone induces less gastrointestinal mucosal changes than diclofenac retard.
    Becvár R; Urbanová Z; Vlasáková V; Vítová J; Rybár I; Maldyk H; Filipowicz-Sosnowska A; Bernacka K; Mackiewicz S; Gömör B; Rojkovich B; Siro B; Bereczki J; Toth K; Sukenik S; Green L; Ehrenfeld M; Pavelka K
    Clin Rheumatol; 1999; 18(4):273-8. PubMed ID: 10468165
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Treatment of rheumatic diseases with nabumetone. Results of a study using the drug in 18,046 patients].
    Lemmel EM; Stroehmann I
    Fortschr Med; 1988 Apr; 106(12):253-6. PubMed ID: 3260888
    [No Abstract]   [Full Text] [Related]  

  • 76. Therapeutic implications associated with renal studies of nabumetone.
    Aronoff GR
    J Rheumatol Suppl; 1992 Nov; 36():25-31. PubMed ID: 1474532
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, Arthrotec, diclofenac, and naproxen in a population based cohort study.
    Ashworth NL; Peloso PM; Muhajarine N; Stang M
    J Rheumatol; 2005 Nov; 32(11):2212-7. PubMed ID: 16265705
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Etodolac versus naproxen in rheumatoid arthritis: a double-blind crossover study.
    Waltham-Weeks CD
    Curr Med Res Opin; 1987; 10(8):540-7. PubMed ID: 2960494
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study.
    Hawkey CJ; Laine L; Simon T; Quan H; Shingo S; Evans J;
    Gut; 2003 Jun; 52(6):820-6. PubMed ID: 12740337
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [A non-steroidal antirheumatic agent (nabumetone): effectiveness and tolerance in short and long-term use].
    Singer F; Kolarz G; Scherak O
    Z Rheumatol; 1983; 42(2):82-5. PubMed ID: 6410605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.